| 09-May-2006 | S | Astrazeneca Pharma India Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 09, 2006 have approved the following matters subject to the approval of the shareholders at a general meeting:- (a) subdivision of the equity shares of the company which is presently at Rs.10 per share to 5 equity shares of Rs.2/- each.
(b) Issuance of new share certificates representing the sub-divided equity shares and/or crediting the shareholders accounts maintained with the depositories. (c) alteration of the Authorised Capital clause of the Memorandum and Articles of Association by which the new Authorised Capital would be Rs.500,00,000/- divided into 2,50,00,000/- equity shares of Rs. 2/- each. Further, the Board of Director have agreed to convene an
Extraordinary General Meeting of the Company to discuss the above matters on June 06, 2006.
Board has approved the following matters subject to the approval of the shareholders at a general meeting:
1. Subdivision of the equity shares of the Company which is presently at Rs 10 per share to Rs 5 Equity shares of Rs 2/- each.
(As per BSE Bulletin dated on 10/05/2006)
EGM 09/05/2006
To consider the following:
1. Subdivision of the equity shares of the Company which is presently at Rs 10 per share to
Rs 5 Equity shares of Rs 2/- each.
(As per BSE Bulletin dated on 12/05/2006)
Trading Members of the Exchange are requested to note that in Daily Bulletin No. 88/2006 dated 12/05/2006 in the AGM / EGM column, the AGM date was inadvertently published as 09/05/2006 instead of 06/06/2006.Trading Members are requested to take note of it.Inconvenience caused is regretted.
EGM 06/06/2006
To consider the following:
1. Subdivision of the equity shares of the Company which is presently at Rs 10 per share to
Rs 5 Equity shares of Rs 2/- each.
2. Issuance of new share certificates representing the sub-divided equity shares and / or crediting the shareholders accounts maintained with the depositories.
3. Alteration of the Authorised Capital clause of the Memorandum and Articles of Association by which the new Authorised Capital would be Rs 500,00,000/- divided into 2,50,00,000/- equity Shares of Rs 2/- each.
(As per BSE Bulletin dated on 16/05/2006)
EGM 06/06/2006
inter alia, to sub-divide the authorised share capital of the Company, comprising each of the
50,00,000 equity shares of Rs 10/- each into 5 equity shares of Rs 2/- each and accordingly
the existing 50,00,000 equity shares of Rs 10/- each comprising the Issued, Subscribed and
Paid up equity share capital of the Company be divided into 2,50,00,000 equity shares of Rs
2/- each and consequential amendments in the Memorandum and Articles of Association of the Company.
(As per BSE Bulletin dated on 05/06/2006)
Astrazeneca Pharma India Limited has informed the Exchange that the Board of Directors
of the company has fixed a Record Date of June 22,2006 for purpose of Sub-Division/Stock Split of Rs.10/- per Share of the Company into 5 Equity Shares of Rs.2/- each.
(As per NSE Bulletin dated on 07/06/2006)
The company has informed that the members at the Extra Ordinary General Meeting (EGM) of the Company held on June 06, 2006, inter alia, have sub-divide the authorised share capital of the Company, comprising each of the 50,00,000
equity shares of Rs 10/- each into 5 equity shares of Rs 2/- each and accordingly the existing 50,00,000 equity shares of Rs 10/- each comprising the Issued, Subscribed and Paid up equity share capital of the Company be divided into 2,50,00,000 equity shares of Rs 2/- each and consequential amendments in the Memorandum and Articles of
Association of the Company.
(As Per BSE Bulletin Dated on 08/06/2006)
Trading members of the Exchange are hereby informed that, AstraZeneca Pharma India Limited has fixed the Record Date for the purpose of sub division.
RECORD DATE 22/06/2006
REDUCED PAID-UP VALUE Rs.2/-
REDUCED PAID-UP VALUE W.E.F. 15/06/2006
Sub Division of existing equity shares from every ONE equity share of Rs.10/- each into FIVE equity shares of Rs.2/- each.
The auction in the equity shares of AstraZeneca Pharma India Limited in Dematerialised Securities - Rolling Settlement Segment on 15/06/2006, 16/06/2006 and 19/06/2006 will be conducted as per face value of Rs.10/- each. Trading members are, therefore, requested to take abundant precautions while mentioning the rates for offering the equity shares of the said company in auction on the said dates.
The scrip will be No Delivery from 15/06/2006 (DR-054/2006-2007) to 21/06/2006 (DR-058/2006-2007).
Note :-
i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route Scheme will be for Rs.2/- paid up w.e.f. 15/06/2006.
ii. ISIN No. INE203A01012 of Rs.10/- paid up will not be valid for transactions done on the Exchange on or after 15/06/2006, except for the auction transactions, which will be conducted on 15/06/2006, 16/06/2006 and 19/06/2006 respectively.
iii. The new ISIN Number for Rs.2/- paid up will be informed to the market by a separate notice.
(As per BSE Notice dated on 09/06/2006) | 22-Jun-2006 | |
| 27-May-2024 | D | We wish to inform that at the meeting of Board of Directors of the Company held on May 27, 2024, the Board has recommended dividend of Rs. 24/- per equity share of Rs. 2/- each subject to the approval of the shareholders at the forthcoming AGM of the Company.
Further to our intimation dated May 27, 2024, we wish to inform that the Record Date for determining the entitlement of the shareholders for the payment of Final Dividend for the financial year is July 5, 2024. The Final Dividend, if approved by the shareholders, shall be paid/ dispatched to the shareholders on or before September 6, 2024.
(As Per BSE Announcement dated on 25.06.2024) | 05-Jul-2024 | |
| 30-May-2023 | D | The Board of Directors of the Company at its Meeting held today i.e., May 30, 2023, inter alia, recommended Dividend of Rs. 16/- per equity share for the Financial Year 2022-23 | 14-Jul-2023 | |
| 26-May-2022 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2022, inter alia, has recommended Final Dividend of Rs. 8/- per equity share for the financial year 2021-22.
Further to our intimation dated May 26, 2022, we wish to inform that the Record Date for determining the entitlement of the shareholders for the payment of the Final Dividend for financial year 2021-22 is July 8, 2022. The Final Dividend, if approved by the shareholders, shall be paid/dispatched to the shareholders on or before September 6, 2022.
(As Per BSE Announcement Dated on 27/06/2022)
| 07-Jul-2022 | |
| 09-Aug-2021 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 09, 2021, inter alia, has declared Interim Dividend of Rs. 2 per equity share for the financial year 2021-22. | 18-Aug-2021 | |
| 10-Aug-2020 | D | We would wish to inform that at the Meeting of the Board of Directors of the Company held today i.e., on August 10, 2020, the Board have inter-alia declared an Interim Dividend of Rs. 2/- per equity share.
The Board of Directors have fixed August 21, 2020 as the Record Date for determining the entitlement of the shareholders for the payment of aforesaid Interim Dividend.
The Interim Dividend shall be paid/dispatched to the shareholders on or before September 8, 2020.
We refer to our letter dated August 10, 2020 wherein the Company had informed that the Interim Dividend declared by the Board of Directors at their meeting held on August 10, 2020 shall be paid on or before September 8, 2020.
In this regard, we confirm that the Company has completed dispatch of interim dividends through electronic mode to all those shareholders whose bank accounts were registered with the Company / Depositories. However, with regard to those shareholder whose bank account details are not registered, the physical instruments for the dividends are being dispatched to their registered address.
In view of the current COVID-19 pandemic situation, the physical dispatches is taking a slightly longer time than usual. The Company is making best efforts to ensure that that the physical instruments/ DDs are dispatched within best possible timelines.
(As Per BSE Announcement Dated 08.09.2020) | 20-Aug-2020 | |
| 07-Aug-2019 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at their meeting held on August 07, 2019, inter alia, has declared Interim Dividend of Rs. 1 (One) per equity share for the financial year 2019-20. | 20-Aug-2019 | |
| 12-May-2012 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 11, 2012, inter alia, has transacted the following:
1. Recommended a Dividend of Rs. 3.50/- per Equity Share of face value of Rs. 2/- each (175%) for the Financial Year ended March 31, 2012, subject to the approval of the shareholders at the ensuing Annual General Meeting. | 09-Jul-2012 | |
| 13-May-2011 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 13, 2011, inter alia, has approved / noted the following:
1. Recommended a Dividend of Rs. 10/- per Equity Share of face value if Rs. 2/- each for the Financial Year (15 months period) ended March 31, 2011, subject to the approval of the shareholders at the ensuing Annual General Meeting. | 07-Jul-2011 | |
| 23-Feb-2010 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 23, 2010, inter alia, has approved/noted the following:
Recommendation of Dividend / Annual General Meeting
Recommended a Dividend of Rs. 10/- per Equity Share of face value of Rs. 2/- each for the year ended December 31, 2009, subject to the approval of the shareholders at the ensuing Annual General Meeting. | 06-May-2010 | |
| 18-Feb-2009 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 18, 2009, inter alia, has transacted the following:
Recommendation of Dividend
The board has recommended a Dividend of Rs 15/- per Equity Share of face value of Rs 2/- each, subject to the approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on May 18, 2009. | 30-Apr-2009 | |
| 25-Feb-2008 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 25, 2008, inter alia, has recommended of Rs 15/- (Previous year Rs 12) as dividend per Equity Share of Rs 2/- each for the year ended December 31, 2007. | 11-Apr-2008 | |
| 23-Feb-2007 | D | AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 23, 2007, inter alia, has decided to transfer Rs 50 million to General Reserves. The Board has also recommended declaration of Dividend of Rs 12/- per equity share (Face Value Rs 2/- each) subject to the approval of the shareholders at the ensuing Annual General Meeting.
AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 17, 2007, inter alia, has transacted / approved the following:
1. The Board has revoked the dividend of Rs 12/- per equity share (face value of Rs 2/-
each), recommended earlier at its meeting held on February 23, 2007.
2. The Board has declared an Interim Dividend of Rs 12/- per equity share (face value of
Rs 2/- each), for the year ended December 31, 2006.
3. Revised Audited Accounts for the year ended December 31, 2006, after necessary changes as to revocation of recommended dividend and payment of Interim Dividend as above, was approved by the Board.
(As Per BSE Announcement Website Dated on 19/03/2007) | 22-Mar-2007 | |
| 20-Mar-2006 | D | 200% Final Dividend | 12-Apr-2006 | |
| 27-Dec-2007 | B | SUB. :- Scheme of Arrangement of AstraZeneca Pharma India Ltd. (Scrip Code 506820)
Trading members of the Exchange are hereby informed that AstraZeneca Pharma India Ltd. has fixed the Record Date for the purpose of
determining entitlement to the shareholders of the company pursuant to the Scheme of Arrangement of the company.
COMPANY NAME CODE
AstraZeneca Pharma India Ltd.
506820
RECORD DATE
11/01/2008
PURPOSE
Scheme of Arrangement
The Company shall issue and allot out of its General Reserve to each shareholders by way of distribution as bonus Debentures (8% Secured fully paid up Redeemable Non-Convertible Bonus Debentures of Rs.25/- each), in the ratio of 1 (ONE) Debenture of the face value of Rs. 25/- each for every 1 (ONE) Equity share of Rs.2/- held by them.
EX-ENTITLEMENT DATE & SETT. NO.
04/01/2008 DR-195/2007- 2008
Note: 8% Secured fully paid up Redeemable Non-Convertible Bonus Debentures of Rs.25/- each will be redeemed in full at the end of 12 months from the date of allotment.
The scrip will be in No Delivery from 04/01/2008 (DR-195/2007-2008) to 10/01/2008 (DR-199/2007-2008). | 11-Jan-2008 | 1:1 |
| 22-Nov-2024 | BC | Please find the enclosed Postal Ballot Notice dated November 13 2024 for your reference. | 22-Dec-2024 | |
| 25-Oct-2024 | BC | ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve the Unaudited Financial Results o | 13-Nov-2024 | |
| 13-Nov-2024 | BC | Please find the enclosed intimation of the Company for the appointment of Mr. Jesus Javier Diaz Ropero Esteso as an Additional Director of the Company w.e.f. November 13, 2024. | 13-Nov-2024 | |
| 25-Sep-2024 | BC | Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform the below: 1. Based on the recommendation of the Nomin | 29-Sep-2024 | |
| 25-Sep-2024 | BC | Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform the below: 1. Based on the recommendation of the Nomin | 25-Sep-2024 | |